Seventy Reason to Buy PAA

In recent previous announcements by PAA it would have been seen that the terms “ Neurodegenerative disease and other age related illnesses “ has been mentioned. I thought it may be interesting to expound on what PAA meant.

This post relates to Monepantal and its related compounds namely mTOR ( mammalian Target OF Rapamycin) and the use of it’s related compound of aminoacenitrile derivatives in the treatment of mTOR pathway related diseases and importantly how MPL induces autophagy.

From an anectoctal perspective we HC members are mostly aware of its potential benefits. But this research may enlighten some.

The compound Monepantal has been studied to some degree and has been found to be potentially a cure for some disease progression but it may have more jewels than what has previously been reported.

A possible cure for.

1. Diseases related to transplant rejection.
2. Chronic Inflammatory Disease.
3. Diseases related to glycogen storage.
4.Systemic Lupus.
5. Diseases related to Inflammation and immune activation.
6. Covid - 19
7. Anaemia
8. Leucopenia.
9. Thrombocytopenia.
10. Diseases related to stent coatings.
11. Renal insufficiency.
12. Obesity.
13. Diabetes Insulin resistance.
14. Diseases relating to non fatty liver.
15. Polycystic kidney and fibrosis.
16. Alzheimer’s Disease.
17. Huntington’s Disease.
18. Parkinson’s Disease.
19. Bladder Cancer.
20. Breast Cancer
21. Colon Cancer.
22. Mesothellioma.
23. Kidney Cancer.
24. Liver Cancer.
25. Small cell lung cancer.
26. Non small cell lung cancer.
27. Head and Neck cancer.
28. Oesophageal Cancer.
29. Gall Bladders cancer.
30. Ovarian Cancer.
31. Pancreatic Cancer.
32. Cancer of the Stomach.
33. Cervical Cancer.
34. Thyroid Cancer.
35. Prostate Cancer.
36. Squamous cell carcinoma.
37. Hematopoietic tumours of lymphoid lineage.
38. Leukaemia.
39. Acute lympathic Leukaemia.
40. Acute lymphoblastic Leukaemia.
41. B cell Lymphoma.
42. T cell Lymphoma.
43. Hodgkin lymphoma.
44. Non Hodgkin lymphoma.
45. Hairy cell lymphoma.
46. Mantle cell lymphoma.
47. Myeloma.
48. Burketts Lymphoma.
49. Myelongenous Lymphoma.
50. Myelodyspastic syndrome.
51. Promyelocyte Leukaemia.
52. Mesenchymal tumours.
53. Fibrosarcoma.
54. Rhadyosarcoma.
55. Astrocytoma
56. Neuroblastoma.
57. Glioma.
58. Schwannomas.
59. Seminoma.
60. Teratocarcinoma.
62. Osteosarcoma.
63. Xenoderoma Pigmentosum.
64. Keratoctanthoma.
65. Thyoid Follicular Cancer.
66. Kaposi’s sarcoma.
67. All above to 2033 via patent.
68. Cash in the bank leave us with many quarters of research.
69. Epichem is a on going growth business.
70. Last but possibly the best is that Phase 1 human trials completed.

References : US patent application number US15/613635.

DYOR

Regards kpax.